VLST Corporation Appoints Brian Blackman as Vice President, Finance & Administration

SEATTLE--(BUSINESS WIRE)-- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced the appointment of Brian Blackman as Vice President, Finance and Administration.

Blackman joins VLST from BN ImmunoTherapeutics, Inc., a subsidiary of Bavarian Nordic, Inc., where he served as director, business operations since 2008. Prior to that, Blackman was senior manager, business development for Dendreon Corporation from 2005 to 2008, joining Dendreon in 2004 as senior area finance manager. His career in financial management has also included work at Penton Media, Inc., as senior financial analyst and Amgen, Inc., serving as financial analyst for Amgen Colorado.

Blackman received a B.S. in Finance from the University of Colorado at Boulder and an M.B.A. from London Business School, UK.

“Brian brings a wide range of experiences at a critical time in VLST’s development. His background in finance, business development and operations will be crucial to our future growth and success,” said Martin Simonetti, president and chief executive officer of VLST.

“I’m excited to join the VLST team and look forward to contributing to the Company’s future development activities in advancing therapeutic candidates for treatment of inflammation and autoimmunity,” said Blackman.

About VLST

VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies. The VLST discovery platform has primary applications for the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, multiple sclerosis, lupus and diabetes. For more information, please visit www.vlstcorp.com.



CONTACT:

Rathbun Communications, Inc.
Julie Rathbun, 206-769-9219
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.